CAS No.129580-63-8,Satraplatin Suppliers

Products Categories

Pharmaceutical (46)
Organic Chemicals (16)
Others (12)
Reagent (2)
Materials (1)
Catalyst and Auxiliary (1)

Basic Information

Molecular Structure:
CAS No.:	129580-63-8
Name:	Satraplatin
Article Data:	2

Formula:	C₁₀H₂₂Cl₂N₂O₄Pt
Molecular Weight:	500.282
Synonyms:	Platinum,bis(acetato-O)amminedichloro(cyclohexanamine)-, (OC-6-43)-;Cyclohexanamine,platinum complex;BMS 182751;BMY 45594;JM 216;POplat;
Boiling Point:	134.5 °C at 760 mmHg
Flash Point:	32.2 °C
PSA:	81.86000
LogP:	3.70610

Raw Materials

124721-03-5

108-24-7

Country:
Business Type:
All

Lab/Research institutions

Trading Company

Manufacturers

Other
Certificate:
Manufacturer

Enterprise Authentication

ISO

GMP

FDA

HALAL

Display:default sort
Suppiers of more reward points first

New supplier

Total:66 Page 1 of 2 1 2 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 129580-63-8

Chemistry

Molecular Formula: C₁₀H₂₂Cl₂N₂O₄Pt
Molecular Weight: 500.29
Flash Point: 32.2 ºC
Product Name: Satraplatin
CAS Registry Number: 129580-63-8
Boiling Point: 134.5 ºC at 760 mmHg
Synonyms: Bis(acetato-o)amminedichloro(cyclohexanamine)-pt ; Platinum (lv) cis-dichloro-trans-bis(acetato-o)ammine(cyclohexanamine) ; Satraplatin ; JM 216
Following is the molecular structure of Satraplatin (129580-63-8):

Uses

Satraplatin (129580-63-8) is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U.S. Food and Drug Administration. First mentioned in the medical literature in 1993 .Satraplatin is the first orally active platinum-based chemotherapeutic drug; other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously.
It is made available in the United States jointly by Spectrum Pharmaceuticals and GPC Biotech under the name SPERA (Satraplatin Expanded Rapid Access)
Satraplatin (129580-63-8) has also been used in the treatment of lung and ovarian cancers. The mode of action is that the compound binds to the DNA of cancer cells rendering them incapable of dividing